It’s a fact. Your trial is unique. While it may have characteristics similar to other studies, by definition there has to be features that are unique to your trial, not least the patients, sites, timing and protocol. That’s why you can’t commoditise trial quality.
Traditional monitoring practices are poor at identifying quality issues. Over 10% of failed submissions are due to data quality or integrity. What if you could design trial quality in right from the start? And what if you could continue to manage that quality to drive your trial to a successful conclusion?
Well now you can. We can help you design the optimal data for your clinical trial, guiding you through the centralized monitoring process to ensure your trial is fully R2 compliant. We provide the tools, training and support you need to identify and address risk early, saving you time and money, but more importantly, ensuring data quality, operational efficiency and patient safety.
Our approach is different. It’s focused on what’s important to your trial. It’s practical and it’s operational. Our platform helps you quickly identify areas of quality risk and the likely causes of that risk, enabling you to manage that risk early. We don’t believe in meaningless statistics and data visualisation. In a world of big data, it’s still people that have to make decisions. Let us guide you to the right ones.
TRI – Custom trials by data design. Get in touch today to see how we can help your trial.
Join KLIFO and TRI’s masterclass in Risk-Based Monitoring and ICH E6 (R2) Compliance – 5th… Click here to book your place today. Protocol Risk Assessments aren’t optional. ICH E6 (R2) GCP regulations… 12th FEB 2019 | THE BRADFIELD CENTRE Looking to maximise the value and benefits of Risk-Based Monitoring… Removing resistance to RBM one protocol risk assessment at a time … Jan 6th 2019: In…
Join KLIFO and TRI’s masterclass in Risk-Based Monitoring and ICH E6 (R2) Compliance – 5th…
Click here to book your place today. Protocol Risk Assessments aren’t optional. ICH E6 (R2) GCP regulations…
12th FEB 2019 | THE BRADFIELD CENTRE Looking to maximise the value and benefits of Risk-Based Monitoring…
Removing resistance to RBM one protocol risk assessment at a time … Jan 6th 2019: In…
I thoroughly enjoyed the training today. I have been worried about the updated guidelines and not really getting to grips with them, but today really highlighted what our team needs to focus on.Sr Director, Regulatory and Compliance, Large CRO
Thank you very much to you and Tammy for organizing and performing this excellent webinar. It was very interesting and I learnt a lot.Head of Clinical Research, Large African-based CRO
Thank you very much for delivering this very valuable training.Senior CRA, Poland-Based CRO
Thanks for the webinar, I appreciated the extra detail you had that some others I’ve seen lacked!CTO, Large UK-based CRO
We are so happy with the work your team have done – they have integrated into our team seamlessly and provide vital insight and domain knowledge.IT Director, Large Swiss Pharma
We really appreciate the level of organization and thought that you folks have put into the KRIs as it has pushed us to consider them within the context of need and value. We are…Operations Manager, Canadian CRO
I am a starter to RBM and it was absolutely very interesting to understand how RBM could work.Medical data reviewer, Large Pharma
Nice product. Respect to the teams work. I very much like it. In particular the design and items like trending, country level.Head of Innovations and Cross Functional Solutions, Large Pharma
I have to say, I’ve been on SO many web-based instructor led training but I’ve never attended one that was so interactive, easily understood, well explained and not boring! It didn’t feel like a…CRA, Top 5 Large Pharma
Very helpful! Thank you. An important part of our selection of OPRA was the RBM consulting service! We knew we needed a vendor that could lead and teach us so for that we are…VP, Clinical Operations, Mid-Size CRO